Filter the drugs by their COVID-19 status ,phase of research and how they help

COVID-19 is a respiratory disease caused by the SARS-CoV-2 virus. Browse the database of potential drugs for COVID-19 treatment compiled by the AIM tool.
Substance COVID-19 status Phase of research How it helps Latest publication
MPI5
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/07/2020
N-(1,3-Benzodioxol-5-ylmethyl)-6H-indolo[2,3-b]quinoxaline-2-carboxamide
Potential treatment - theoretical effect Experimental Antiviral Dec/04/2020
2-(2,3-Dihydro-1H-indol-1-ylcarbonyl)-N-(3-methylphenyl)quinazolin-4-amine
Potential treatment - theoretical effect Experimental Antiviral Dec/04/2020
Anisomycin
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/02/2020
3,3-Dimethyl-N-[4-(piperidin-1-ylcarbonyl)phenyl]butanamide
Potential treatment - theoretical effect Experimental Antiviral Dec/01/2020
IPAVFK
Potential treatment - theoretical effect Experimental Antiviral Dec/01/2020
ALMPHIR
Potential treatment - theoretical effect Experimental Antiviral Dec/01/2020
ACE2 microbody
Potential treatment - pre-clinical evidence Experimental Antiviral Dec/01/2020
YF-S0
Potential treatment - pre-clinical evidence Experimental Vaccine Dec/01/2020
GSK-256066
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/30/2020
sMVA-N/S
Potential treatment - pre-clinical evidence Experimental Vaccine Nov/30/2020
sMVA-N
Potential treatment - pre-clinical evidence Experimental Vaccine Nov/30/2020
sMVA-S/N
Potential treatment - pre-clinical evidence Experimental Vaccine Nov/30/2020
sMVA-S
Potential treatment - pre-clinical evidence Experimental Vaccine Nov/30/2020
MVC-COV1901
Potential treatment - pre-clinical evidence Experimental Vaccine Nov/29/2020
SARS-CoV-2 RBD-Fc
Potential treatment - pre-clinical evidence Experimental Vaccine Nov/27/2020
H4
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/27/2020
B38
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/27/2020
Candidate vaccine (Wuhan Institute of Biological Products and Wuhan Institute of Virology)
Potential treatment - pre-clinical evidence Experimental Vaccine Nov/26/2020
mAb 1D2
Potential treatment - pre-clinical evidence Experimental Antiviral Nov/26/2020